CLR 1404 I-131

Drug Profile

CLR 1404 I-131

Alternative Names: (131)I-CLR1404; 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine; 131I-CLR1404; 131I-NM 404; CLR 131; CLR1404 I-131; HOT; I-131-CLR1404; NM404

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Drug conjugates; Phospholipids; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Multiple myeloma
  • Phase I/II Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 19 Mar 2018 CLR 1404 I-131 receives Orphan Drug status for Neuroblastoma in USA
  • 19 Mar 2018 The US FDA accepts IND for a phase I trial for Solid tumours and Lymphoma (In children, In adolescents) for review before March 2018
  • 19 Mar 2018 Cellectar Biosciences plans a phase I trial for Solid tumours and Lymphoma (In children, In adolescents) in 2Q 2018 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top